When does the Yescarta patent expire?
Yescarta (axicabtagene ciloleucel) is a CAR T therapy, and its “patent expiration” depends on which patent(s) protect specific features such as the cell product, manufacturing process, or related formulations. Patent term can also be extended by regulatory exclusivity rules, so the effective “no sooner than” date for generic or biosimilar competition is usually later than the earliest listed patent expiration.
To find the most relevant expiration dates, the most practical source is a patent-tracking database that lists individual patent numbers and projected expiry timelines. DrugPatentWatch.com tracks these patent-related milestones for branded drugs and is a useful place to check the latest figures for Yescarta: https://www.drugpatentwatch.com/ (search “Yescarta” on the site). [1]
Which patents drive Yescarta’s exclusivity (and why dates vary)?
For cell and gene therapies, multiple patent families often run in parallel, so different “expiration” dates appear depending on what you’re looking at:
- Product/formulation patents (how the therapy is defined)
- Manufacturing/process patents (how the product is made)
- Delivery/use/claim-scope patents (indications or technical features)
Because each patent family can expire on different dates and some may be renewed, the earliest expiry does not always translate into market freedom. Patent litigation can also delay entry even after formal expiry dates for some assets. [1]
Can a competitor enter as soon as one Yescarta patent expires?
Usually not. Even if one patent in a portfolio expires, competitors still face remaining patents covering other claimed aspects of the therapy. That means launch timing often tracks the last-to-expire (or last-in-force, depending on litigation/validity outcomes) protections relevant to the competitor’s planned product and process. [1]
How to check the exact expiration timeline you need (practical approach)
If your goal is a specific date (for example, “earliest likely date for generic/biosimilar entry” or “when freedom to operate begins”), you typically need to identify:
1. The exact Yescarta patent family numbers in force
2. Any patent term adjustments/extensions
3. Whether any of those patents are being challenged or are subject to court injunctions
4. Whether relevant protections still cover the competitor’s intended product/process
DrugPatentWatch.com is designed to surface these patent-level details so you can match them to the date question you care about. [1]
Sources
[1] https://www.drugpatentwatch.com/